Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. Finance cost has doubled this quarter mainly due to drawing down limits for Sunshine units. Management stated financing options include using existing limits for capex or drawing from available profits. No definitive commitment or plan for fresh debt or equity issuance was shared. Expansion projects are primarily funded by internal accruals or existing credit limits. The company appears focused on operational growth and capacity ramp-up rather than new external fundraising currently.

Any current/future capex/capital investment/strategic investment?

Capex will start mostly from next fiscal year, with significant investment planned for new hospitals and facility expansions. Bangalore: Two hospitals with 750 beds combined, INR 650 crores total outlay (~INR 80 lakhs per bed); one asset 50% owned, other on revenue share model. Thane project: INR 400 crores capex, with construction underway and transaction closure with investor expected soon; operational by Q1 or Q2 of next fiscal. Nashik hospital projected to be operational by Q4 of current financial year or early Q1 next year. Kondapur expansion: Incremental 400 beds planned to begin two yea

Future growth expectations in sales/revenue/volumes?

Telangana and Andhra Pradesh clusters continue revenue growth at 15% YoY, with room for new specialty additions (oncology, mother & child care, interventional procedures) to drive further growth. Incremental bed additions of ~1500 beds in Andhra and Telangana over 24-36 months, maintaining occupancy around 70-75%. Sunshine and Nagpur hospitals expected to scale up with improved occupancy and doctor additions, contributing positively to revenue. New facilities in Bangalore (750 beds) to start operations between Q1 and Q2 FY25, with significant capex (~INR 650 crores). Thane and Nashik projects

Future growth expectations in earnings/operating earnings/profits/EPS?

Incremental revenue growth driven by onboarding 25-30 new doctors leading to higher earnings. Telangana and Andhra Pradesh clusters expected to maintain and improve EBITDA margins; Telangana targets 30% margin in 24 months, Andhra Pradesh aims for 25%-27%. Sunshine and Nagpur facilities anticipated to improve margins and revenues as new hospitals scale up. New pediatric and mother-child specialty services expected to contribute to revenue growth without significant pricing hikes. Expansion in Bangalore (750 beds), Thane, and Nagpur to add capacity with expected gradual EBITDA margin stabilizat

Krishna Institu.Q1 FY24Healthcare Services

Krishna Institu. Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹736P/E: 157.1Market Cap: ₹32.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Telangana and Andhra Pradesh clusters continue revenue growth at 15% YoY, with room for new specialty additions (oncology, mother & child care, interventional procedures) to drive further growth.
Incremental bed additions of ~1500 beds in Andhra and Telangana over 24-36 months, maintaining occupancy around 70-75%.
Sunshine and Nagpur hospitals expected to scale up with improved occupancy and doctor additions, contributing positively to revenue.
New facilities in Bangalore (750 beds) to start operations between Q1 and Q2 FY25, with significant capex (~INR 650 crores).
Thane and Nashik projects progressing with expected capacity additions.
ARPOB (Average Revenue Per Occupied Bed) expected to grow at a blended 3-5% rate, driven mainly by new clinical therapies and pricing from insurance.
EBITDA margins anticipated to improve as new facilities mature, with incremental revenue converting 40% directly to EBITDA in key clusters.

Margin guidance

Category 3

Incremental revenue growth driven by onboarding 25-30 new doctors leading to higher earnings.
Telangana and Andhra Pradesh clusters expected to maintain and improve EBITDA margins; Telangana targets 30% margin in 24 months, Andhra Pradesh aims for 25%-27%.
Sunshine and Nagpur facilities anticipated to improve margins and revenues as new hospitals scale up.
New pediatric and mother-child specialty services expected to contribute to revenue growth without significant pricing hikes.
Expansion in Bangalore (750 beds), Thane, and Nagpur to add capacity with expected gradual EBITDA margin stabilization.
ARPOB growth expected around 3%-5% blended, driven mainly by case mix and new therapies rather than price increases.
Corporate overheads and higher consumable costs currently suppress margins but expected to normalize with scale.
Overall, incremental revenues in Telangana and Andhra are expected to yield approximately 40% EBITDA flow-through, supporting strong profit growth.

See what Krishna Institu. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
Finance cost has doubled this quarter mainly due to drawing down limits for Sunshine units.
Management stated financing options include using existing limits for capex or drawing from available profits.
No definitive commitment or plan for fresh debt or equity issuance was shared.
Expansion projects are primarily funded by internal accruals or existing credit limits.
The company appears focused on operational growth and capacity ramp-up rather than new external fundraising currently.

Order book

The transcript does not explicitly mention details about the current or expected order book or pending orders related to KIMS Hospitals. The discussions primarily cover operational updates, expansion plans, bed additions, revenue growth, margins, price hikes, doctor specialties, and financial performance for Q1 FY24. There is no direct information provided regarding order book or pending orders for capital expenditure or other contracts. If you seek details on ongoing or future projects, the call highlights expansions in Bangalore, Thane, Nashik, Andhra Pradesh, Telangana, Sunshine Hospital ramp-up, and Nagpur hospital, which could imply ongoing investment and operational buildup, but no quantified order book or pending order data is shared.

See what Krishna Institu. management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex will start mostly from next fiscal year, with significant investment planned for new hospitals and facility expansions.
Bangalore: Two hospitals with 750 beds combined, INR 650 crores total outlay (~INR 80 lakhs per bed); one asset 50% owned, other on revenue share model.
Thane project: INR 400 crores capex, with construction underway and transaction closure with investor expected soon; operational by Q1 or Q2 of next fiscal.
Nashik hospital projected to be operational by Q4 of current financial year or early Q1 next year.
Kondapur expansion: Incremental 400 beds planned to begin two years from now.
Expansion in Andhra with new oncology centers and mother & child care units across multiple facilities.
Emphasis on ramping up Sunshine and Nagpur hospitals, including shifting OPD/IPD in Sunshine from August.
Corporate overhead costs currently impacting Telangana cluster margins due to expansion activities.

Track Krishna Institu. — get its next earnings analysis in your feed

How does Krishna Institu. rank vs peers in Healthcare Services?

Pro feature

ThisKrishna Institu.

Rev 3Mar 3

See where Krishna Institu. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Krishna Institu. rank in Healthcare Services?

Compare Krishna Institu. against every Healthcare Services company (Q1 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Krishna Institu.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Krishna Institu. Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Krishna Institu. rank in Healthcare Services?

Continue your research

What Krishna Institu.'s management said in earlier quarters

Others in Healthcare Services this season